PRTK (Update)

Paratek Pharmaceuticals Inc

Healthcare


Presented:06/06/2018
Price:$10.65
Cap:$0.33B
Current Price:$2.23
Cap:$0.13B

Presented

Date06/06/2018
Price$10.65
Market Cap$0.33B
Ent Value$0.27B
P/E RatioN/A
Book Value$3.52
Div Yield0%
Shares O/S30.57M
Ave Daily Vol619,335
Short Int10.18%

Current

Price$2.23
Market Cap$0.13B
Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include Omadacycline and Sarecycline, which are used for the treatment of serious community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, and urinary tract infections. The company was founded in February 2001 and is headquartered in Boston, MA.

Please note, this is an update to Paratek Pharmaceuticals Inc (PRTK) - Long, which was originally presented on 5/11/2018.

Publicly traded companies mentioned herein: Allergan PLC (AGN), Merck & Co Inc (MRK), Paratek Pharmaceuticals Inc PRTK), Pfizer Inc (PFE), Zai Lab Ltd (ZLAB)

Highlights

The presenter remains long shares of Paratek Pharmaceuticals (PRTK) and views the recent decline as a potential buying opportunity. With the advisory committee meeting for omadacycline one month closer (August); UTI data in 2H 2018; an October PDUFA date [for omadacycline]; and underappreciated value in the pipeline, and the Zai Labs partnership, he continues to see a favorable longer-term risk/reward.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.